Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.


NDAQ:AZN - Post by User

AstraZeneca ADR Representing 0.5 Ord Shs
<< Previous
 Bullboard Posts
User Avatar Image
(240)
•••
Post by whytestockson Jul 25, 2024 10:16pm
101 Views
Post# 36149191

AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript

AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript
News; $AZN AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript2024-07-25 11:45:11 ET Image source: The Motley Fool. AstraZeneca Plc (NASDAQ: AZN) Q2 2024 Earnings Call Jul 25, 2024 , 6:45 a.m. ET Operator Continue reading For further details see: AstraZeneca Plc (AZN) Q2 2024 Earnings Call TranscriptAZN - AstraZeneca Plc (AZN) Q2 2024 Earnings Call Transcript

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities